D. Van-der-heijde, B. Dijkmans, P. Geusens, J. Sieper, K. Dewoody et al., Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT), Arthritis & Rheumatism, vol.50, issue.2, pp.582-591, 2005.
DOI : 10.1002/art.20852

H. Haibel, H. Brandt, I. Song, A. Brandt, J. Listing et al., No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial, Annals of the Rheumatic Diseases, vol.66, issue.3, pp.419-421, 2007.
DOI : 10.1136/ard.2006.054098

L. Altan, U. Bingol, Y. Karakoc, S. Aydiner, M. Yurtkuran et al., Clinical investigation of methotrexate in the treatment of ankylosing spondylitis, Scandinavian Journal of Rheumatology, vol.32, issue.6, pp.255-259, 2001.
DOI : 10.1080/03009740410005089

L. Gonzalez-lopez, A. Garcia-gonzalez, M. Vazquez-del-mercado, J. Muñoz-valle, and J. Gamez-nava, Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial, J Rheumatol, vol.31, pp.1568-1574, 2004.

B. Roychowdhury, S. Bintley-bagot, D. Bulgen, R. Thompson, E. Tunn et al., Is methotrexate effective in ankylosing spondylitis? Rheumatology (Oxford), pp.1330-1332, 2002.

J. Chen, C. Liu, and J. Lin, Methotrexate for ankylosing spondylitis, Cochrane Database Syst Rev, vol.4, p.4524, 2006.

V. Pérez-guijo, A. Cravo, C. Mdel, C. Font, P. Muñoz-gomariz et al., Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis, Joint Bone Spine, vol.74, issue.3, pp.254-258, 2007.
DOI : 10.1016/j.jbspin.2006.08.005

M. Breban, P. Ravaud, P. Claudepierre, G. Baron, Y. Henry et al., Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment, Arthritis & Rheumatism, vol.54, issue.1, pp.88-97, 2008.
DOI : 10.1002/art.23167
URL : https://hal.archives-ouvertes.fr/inserm-00217374

T. Pham, B. Fautrel, E. Dernis, P. Goupille, F. Guillemin et al., Recommendations of the French Society for Rheumatology regarding TNF?? antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update, Joint Bone Spine, vol.74, issue.6, pp.638-646, 2007.
DOI : 10.1016/j.jbspin.2007.10.003

S. Van-der-linden and H. Valkenburg, Evaluation of Diagnostic Criteria for Ankylosing Spondylitis, Arthritis & Rheumatism, vol.2, issue.4, pp.361-368, 1984.
DOI : 10.1002/art.1780270401

J. Braun, T. Pham, J. Sieper, J. Davis, S. Van-der-linden et al., van der Heijde D: International ASAS consensus statement for the use of antitumour necrosis factor agents in patients with ankylosing spondylitis

D. Ternant, D. Mulleman, D. Degenne, S. Willot, J. Guillaumin et al., An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Infliximab, Therapeutic Drug Monitoring, vol.28, issue.2, pp.169-174, 2006.
DOI : 10.1097/01.ftd.0000189901.08684.4b

R. Krzysiek, M. Breban, P. Ravaud, M. Prejean, J. Wijdenes et al., Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control study, Arthritis & Rheumatism, vol.4, issue.5, pp.569-576, 2009.
DOI : 10.1002/art.24275

K. Visser, W. Katchamart, E. Loza, J. Martinez-lopez, C. Salliot et al., Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative, Annals of the Rheumatic Diseases, vol.68, issue.7, pp.1086-1093, 2009.
DOI : 10.1136/ard.2008.094474

M. De-vries, G. Wolbink, S. Stapel, H. De-vrieze, J. Van-denderen et al., Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation, Annals of the Rheumatic Diseases, vol.66, issue.9, pp.1252-1254, 2007.
DOI : 10.1136/ard.2007.072397

R. Maini, F. Breedveld, J. Kalden, J. Smolen, D. Davis et al., Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis & Rheumatism, vol.6, issue.9, pp.1552-1563, 1998.
DOI : 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W

S. Hanauer, B. Feagan, G. Lichtenstein, L. Mayer, S. Schreiber et al., Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, The Lancet, vol.359, issue.9317, pp.1541-1549, 2002.
DOI : 10.1016/S0140-6736(02)08512-4

F. Baert, M. Noman, S. Vermeire, G. Van-assche, D. Haens et al., Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease, New England Journal of Medicine, vol.348, issue.7, pp.601-608, 2003.
DOI : 10.1056/NEJMoa020888

K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M. Kapetanovic et al., Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor ?? inhibitor infliximab, Arthritis & Rheumatism, vol.45, issue.12, pp.3782-3789, 2006.
DOI : 10.1002/art.22214

G. Wolbink, A. Voskuyl, W. Lems, E. De-groot, M. Nurmohamed et al., Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.64, issue.5, pp.704-707, 2005.
DOI : 10.1136/ard.2004.030452